

FRIDAY 28 OCTOBER		SATURDAY 29 OCTOBER		SUNDAY 30 OCTOBER			
		Venue CIG		Venue: CIG			
		Amphithéâtre D 892 pax	Plenary B&C 456 pax				
		08:15 - 09:30	Plenary Rapid Fire Updates	08:30 - 09:30	Plenary - Oral abstracts		
			Opening remarks				
			Updates on surgery				
			Updates on haematology				
			Updates on geriatrics				
			Updates on translational research				
			Updates on radiation				
			Updates on oncology				
		09:30 - 10:30	Short abstracts	Learning from randomized trials: Do GA interventions improve outcomes?	09:30 - 10:30	PROM, focusing on financial toxicity, sexual dysfunction, cognition decline and PROMs	
				Talk 1: Geriatric Oncology RCTs: State of the Art		Talk 1: Practice-changing chemotherapy studies: EWOC-1, NORDIC 9 etc.	
			Talk 2: GAP/GAIN studies (GA to decrease toxicity)		Talk 2: Key updates in immunotherapy		
			Talk 3: GO-SAFE		Talk 3: Prehabilitation: key studies in the surgical oncology field		
			Talk 4: 5c study-geriatric consultation to improve QOL (negative primary outcome)				
			Talk 5: Summary of additional RCTs and overall learnings				
10:00-12:30	SIOG Public Policy Meeting Venue United Nations Room XVIII (18), Building E, Door E40 1st Floor			30 mins			
	Agenda TBC						
		10:30 - 11:00	Networking break		10:30 - 11:00	Networking break	
		11:00 - 12:00	MDT Maximal treatment vs deescalation Ovarian cancer and Gastric cancer	11:00 - 12:00	MDT - Science Slam	Immunotherapy in older adults with cancer - Rethinking the toxicity of treatment	
		11:00 - 11:30	Case = 'vulnerable' patient (not fit, not very frail) with new diagnosis of ovarian cancer		Case 1: AML, intermediate risk/borderline allo eligible	Talk 1: Toxicity of immunotherapy in older adults - the scale of the problem	
		11:30 - 12:00	Case = 'vulnerable' patient (not fit, not very frail) with new gastric cancer		Case 2: lymphoma/CARTs?	Talk 2: What is the impact of immunotherapy toxicity on frail older adults?	
			Expert panel: Surgeon perspective Geriatrician perspective Medical Oncologist perspective Nurse perspective		Expert panel: Geriatrician perspective Nurse perspective Two hematologists perspectives	Talk 3: Toxicity management - What is the impact of corticosteroids on older adults with cancer?	
						Talk 4: Is it time for a paradigm shift? What is the role of DMARDs in toxicity management?	
		12:00 - 14:00	LUNCH BREAK / Industry Symposia		12:00 - 14:00	LUNCH BREAK / Industry Symposia	
14:00 - 15:00	Geriatric Assessment Workshop Venue CIG	14:00 - 15:00	Biology of aging	14:00 - 15:00	Survivorship and Resilience in Hematologic Malignancies	Let's talk about study methods	
			Talk 1: Aging and anticancer therapies		Talk1: Survivorship Issues in multiple myeloma (including vaccination strategies)	Talk 1 - Organizing a personal database (pitfalls and pearls of how to make it simple and generate data quickly)	
			Talk 2: Biomarkers of aging		Talk 2: Lymphoma survivorship: the role of cardiovascular follow-up, CHIP and the risk of T-AML	Talk 2: Linking your research efforts with a multidisciplinary team	
			Q&A		Talk 3: Modifying survivorship in CLL with targeted therapies: Can we stop treatment with achievement of MRD negativity?	Talk 3: Use of Large databases in geriatric oncology	
						Talk 4: Interpretation of Randomized clinical trials	
						Talk 5: Data sharing agreements and opportunities for international research collaboration	
						Talk 6: Debate on Big Data	
						Big Data Gives Big Information (Pro)	
						Big Data is Really Quite Small (Con)	
		15:00 - 16:00	Setting up oncogeriatric care services using the Consultative Geriatric Oncology Model: Experiences from across regions	15:00 - 16:00	Joint session EuGMS/SIOG Sarcopenia in older adults with cancer	Short abstracts	
			Talk 1: Geriatrician experience		Talk 1: An overview of sarcopenia in older adults with cancer (to include definition, screening and consequences)		
			Talk 2: Nursing experience		Talk 2: Review of imaging technology in the diagnosis of sarcopenia (to include CT and BIA)		
			Talk 3: Developing country experience		Talk 3: Exercise as an interventional strategy for sarcopenia		
			Concluding remarks				
		16:00 - 16:30	Networking break		16:00 - 16:30	Networking break	
		16:30 - 17:30	Intrinsic capacity as measure of resilience in older adults	16:30 - 17:30	Plenary - Presidential Session		
			Operationalizing resilience in older adults with cancer from frailty management to enhancement of intrinsic capacity				
			Talk 1: Insights from a low- and middle- income country.				
			Talk 2: -Be-enforcing comprehensive geriatric assessment (CGA) with newer concepts of intrinsic capacity				
			Talk 3: Measures of Resilience- Resilience in the Older Cancer Patient: what it is, why it matters, how to assess/measure, and why it represents an incredible opportunity for future research and improving patient outcomes				
			Talk 4: Resilience in the Older Cancer Patient: what it is, why it matters, how to assess/measure, and why it represents an incredible opportunity for future research and improving patient outcomes				